Novozymes And Chr. Hansen Complete Merger
After announcing their initial plans to combine companies in late 2022, Novozymes and Chr. Hansen have officially merged to form Novonesis.
The term “novonesis” means “a new beginning”, something the company says is offered through their biology-based products.
“Novonesis combines our joint strengths and the wonders of biology, and we are set to lead a new era of biosolutions. We will innovate and develop transformative biosolutions that improve the way we all produce, consume and live. And we have gathered the brightest minds and together with my 10,000 colleagues, we will unlock the limitless potential of biosolutions,” says Ester Baiget, president and CEO of Novonesis.
The company reports an annual revenue of approximately 3.7 billion EUR, or about $4 billion, following the merger with 10,000 employees and 60 sites and centers worldwide.
While Novozymes was focused on agriculture, biofuels and household products and Chr. Hansen rooted in the food sector, together they share half of the business’ portfolio will focus on healthier lives and foods while the other half focuses on reducing chemical use and working toward climate neutrality. By 2030, Novonesis’ goal is to reduce their operations emissions by 75% and supply chain emissions by 35%.
“We will continue to create powerful biosolutions for our customers and partners based on our more than 100 years of innovation and application expertise,” says Cees de Jong, chairman of Novonesis. “Together, we will serve as a growth partner to our customers, a value creator to our shareholders, and a company that has a significant, positive impact on society and the planet. Novonesis builds on a shared heritage of sustainability leadership and will keep leading the way."
